Chulalongkorn Medical Journal


Background: Patients with chronic obstructive pulmonary disease (COPD) usually suffer from breathlessness caused by chronic progressive worsening of airway obstruction and lung hyperinflation. Objective: This study aimed to evaluate the effects of fenoterol hydrobromide and ipratropium bromide combination on lung function parameters in Thai COPD patients. We also compared the effects from two commercially available products; Aerobidol® metered-dose inhaler (MDI) and Berodual® inhaler. Methods: A double-blind, randomized cross-over study was conducted in 31 COPD patients from outpatient service, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. To compare the responses of both inhalers on lung volume parameters, patients were randomized to be challenged by either Aerobidol® MDI or Berodual® inhaler. Spirometry and body plethysmography were performed before and after 60 min of each inhalation administration. All patients were switched to the other inhaler in the same manner after one-week washout period. A change of lung volume parameters including forced expiratory volume in the first second (FEV1), inspiratory capacity (IC), functional residual capacity (FRC), and residual volume (RV) were statistically compared by using analysis of covariance. Results: Thirty-one COPD patients were recruited into the study. Their average of age was 66.6 years with a median value of smoking of 40 pack-years. Severity of COPD according to post bronchodilator FEV1 % predicted was mainly in GOLD stage 2 and 3. Both Aerobidol® MDI and Berodual® inhaler significantly ncreased FEV1 and decreased RV from baseline values. No statistical difference in changes of FEV1 , IC, FRC, and RV between these two inhalers were observed. Conclusion: Acute bronchodilating effects of Aerobidol® MDI is comparable to Berodual® inhaler in Thai COPD patients.


Faculty of Medicine, Chulalongkorn University



First Page


Last Page